“Lymphoproliferative Skin Lesion As a Previously Unreported Adverse Event Detected in a Patient Receiving MSTR TB Treatment”. 2022. Journal of Pharmacovigilance and Drug Research 3 (2): 34-37. https://doi.org/10.53411/jpadr.2022.3.2.7.